Cancer

[Typhoon]

Nature | In vivo CAR T cells move into clinical trials

Techniques that turn a person’s immune T cells into CAR T cells directly in the body are beginning to be tested in clinical trials. CAR T cells are currently made by removing a person’s own T cells, engineering them to express a cell-surface protein that attacks cancerous cells and reinfusing them into the body. In vivo approaches that insert genetic-engineering tools directly into the body could be far less expensive and would not require people to undergo chemotherapy as part of the treatment. Around 12 companies have launched or soon plan to launch clinical trials testing various genetic constructs, or ‘vectors’, that carry the tools into a person’s T cells.

CAR T - Chimeric Antigen Receptor T-cell therapy

[Nonc Hilaire]

First peer reviewed Fenbedmazole/Mebednazole/Ivermectin cancer protocol.

https://isom.ca/wp-content/uploads/2024 ... M-39.3.pdf

[Typhoon]

First peer reviewed Fenbedmazole/Mebednazole/Ivermectin cancer protocol.

https://isom.ca/wp-content/uploads/2024 ... M-39.3.pdf

Wikipedia | Journal of Orthomolecular Medicine

There are enough problems in medical research today without the addition of the woo-woo crowd.

Anyways, it's a proposed protocol which requires follow-up clinical trials.

Also, people often seem to have a misunderstanding of what peer-review entails. It does not mean that the reported results have been independently checked and verified, rather that the paper was read by fellow peers in the field who did not have any major objections to the content.

Of course, such a system is open to abuse [pal review, gatekeeping, predatory journals, citation farms, etc.]. That it works at all may be considered a minor miracle.